Autor/in Papp, K Blauvelt, A 2 Gooderham, M 2 Maari, C 2 Reich, K 2 Augustin, M 1 Cauthen, A 1 Ferris, L K 1 Gordon, K B 1 Gottlieb, A 1 Jarell, A 1 Langley, R G 1 Lima, R G 1 Lowry, S 1 Mendelsohn, A 1 Osuntokun, O 1 Parno, J 1 Polzer, P 1 Sofen, H 1 Spelman, L 1 Tada, Y 1 Tyring, S 1 Yamanaka, K 1 Zhang, L 1 Zhao, Y 1 alle zeigenListe einklappen
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial Blauvelt, A Papp, K Gottlieb, A Jarell, A Reich, K Maari, C Gordon, K B 2020 - Forschungsinformationssystem des UKE
An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12 Papp, K Maari, C Cauthen, A Gooderham, M Spelman, L Yamanaka, K Polzer, P 2020 - Forschungsinformationssystem des UKE
Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials Blauvelt, A Sofen, H Papp, K Gooderham, M Tyring, S Zhao, Y Lowry, S 2019 - Forschungsinformationssystem des UKE
